@article{527b5e6a4dc34adb8fac83509a98d1a6,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update",
abstract = "Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).",
author = "Karnes, {Jason H.} and Rettie, {Allan E.} and Somogyi, {Andrew A.} and Rachel Huddart and Fohner, {Alison E.} and Formea, {Christine M.} and {Ta Michael Lee}, Ming and Adrian Llerena and Michelle Whirl-Carrillo and Klein, {Teri E.} and Phillips, {Elizabeth J.} and Scott Mintzer and Andrea Gaedigk and Caudle, {Kelly E.} and Callaghan, {John T.}",
note = "Funding Information: This work is funded by National Institutes of Health (NIH) grants CPIC (R24GM115264 and U24HG010135) and PharmGKB (R24 GM61374), R24GM123930 (AG), GM092666 (CEH), GM32165 (AER), UO1 GM092676, and U01 HL0105918. JHK is supported by grants from the NIH{\textquoteright}s National Heart Lung and Blood Institute (NHLBI) under award number K01HL143137, the American College of Clinical Pharmacy, and the Flinn Foundation. AAS is supported by grant APP108798 by the National Health and Medical Research Council of Australia. EJP receives funding from the NIH (R01 HG010863‐01, 1P50GM115305‐01, R21AI139021 and R34AI136815) and NHMRC (APP1123499). Funding Information: This work is funded by National Institutes of Health (NIH) grants CPIC (R24GM115264 and U24HG010135) and PharmGKB (R24 GM61374), R24GM123930 (AG), GM092666 (CEH), GM32165 (AER), UO1 GM092676, and U01 HL0105918. JHK is supported by grants from the NIH?s National Heart Lung and Blood Institute (NHLBI) under award number K01HL143137, the American College of Clinical Pharmacy, and the Flinn Foundation. AAS is supported by grant APP108798 by the National Health and Medical Research Council of Australia. EJP receives funding from the NIH (R01 HG010863-01, 1P50GM115305-01, R21AI139021 and R34AI136815) and NHMRC (APP1123499). The authors acknowledge the critical input of members of CPIC of the Pharmacogenomics Research Network (PGRN), particularly Dr. Mary V. Relling (St. Jude Children?s Research Hospital). Publisher Copyright: {\textcopyright} 2020 The Authors Clinical Pharmacology & Therapeutics {\textcopyright} 2020 American Society for Clinical Pharmacology and Therapeutics",
year = "2021",
month = feb,
doi = "10.1002/cpt.2008",
language = "English (US)",
volume = "109",
pages = "302--309",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",
}